M
Malini Mukherjee
Researcher at Baylor College of Medicine
Publications - 48
Citations - 2516
Malini Mukherjee is an academic researcher from Baylor College of Medicine. The author has contributed to research in topics: Cytotoxic T cell & Notch signaling pathway. The author has an hindex of 19, co-authored 40 publications receiving 1792 citations. Previous affiliations of Malini Mukherjee include Boston Children's Hospital & Center for Cell and Gene Therapy.
Papers
More filters
Journal ArticleDOI
Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Meenakshi Hegde,Malini Mukherjee,Malini Mukherjee,Zakaria Grada,Antonella Pignata,Daniel Landi,Shoba A. Navai,Amanda Wakefield,Kristen Fousek,Kevin Bielamowicz,Kevin Chow,Vita S. Brawley,Tiara T. Byrd,Simone Krebs,Stephen Gottschalk,Winfried S. Wels,Matthew L. Baker,Gianpietro Dotti,Maksim Mamonkin,Malcolm K. Brenner,Jordan S. Orange,Jordan S. Orange,Nabil Ahmed +22 more
TL;DR: TanCAR T cells show therapeutic potential to improve glioblastoma control by coengaging HER2 and IL13Rα2 in an augmented, bivalent immune synapse that enhances T cell functionality and reduces antigen escape.
Journal ArticleDOI
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
Enli Liu,Yijiu Tong,Gianpietro Dotti,Hila Shaim,Barbara Savoldo,Malini Mukherjee,Jordan S. Orange,Xinhai Wan,Xinyan Lu,Alexandra Reynolds,Mihai Gagea,Pinaki P. Banerjee,Rong Cai,Mustafa Bdaiwi,Rafet Basar,Muharrem Muftuoglu,Li Li,David Marin,William G. Wierda,Michael J. Keating,Richard E. Champlin,Elizabeth J. Shpall,Katayoun Rezvani +22 more
TL;DR: A novel approach to immunotherapy is developed using engineered CB-derived NK cells, which are easy to produce, exhibit striking efficacy and incorporate safety measures to limit toxicity, which should greatly improve the logistics of delivering this therapy to large numbers of patients.
Journal ArticleDOI
Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in Glioblastoma
Meenakshi Hegde,Amanda Corder,Kevin Chow,Malini Mukherjee,Aidin Ashoori,Yvonne Kew,Yi Jonathan Zhang,David S. Baskin,Fatima A. Merchant,Vita S. Brawley,Tiara T. Byrd,Simone Krebs,Meng Fen Wu,Hao Liu,Helen E. Heslop,Stephen Gottachalk,Eric Yvon,Nabil Ahmed +17 more
TL;DR: Both HER2/IL-13Rα2-bispecific T cell products offset antigen escape, producing enhanced effector activity in vitro immunoassays and in an orthotopic xenogeneic murine model.
Journal ArticleDOI
Trivalent CAR T cells overcome interpatient antigenic variability in glioblastoma.
Kevin Bielamowicz,Kristen Fousek,Kristen Fousek,Tiara T. Byrd,Tiara T. Byrd,Hebatalla Samaha,Hebatalla Samaha,Malini Mukherjee,Malini Mukherjee,Nikita Aware,Nikita Aware,Meng-Fen Wu,Jordan S. Orange,Jordan S. Orange,Pavel Sumazin,Tsz-Kwong Man,Sujith K. Joseph,Sujith K. Joseph,Meenakshi Hegde,Nabil Ahmed +19 more
TL;DR: Co-targeting HER2, IL13Rα2, and EphA2 could overcome interpatient variability by a tendency to capture nearly 100% of tumor cells in most tumors tested in this cohort and can overcome antigenic heterogeneity in GBM and lead to improved treatment outcomes.
Journal ArticleDOI
Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent.
Diogo Gomes-Silva,Diogo Gomes-Silva,Malini Mukherjee,Malini Mukherjee,Malini Mukherjee,Madhuwanti Srinivasan,Giedre Krenciute,Giedre Krenciute,Olga Dakhova,Yueting Zheng,Joaquim M. S. Cabral,Cliona M. Rooney,Cliona M. Rooney,Jordan S. Orange,Jordan S. Orange,Malcolm K. Brenner,Maksim Mamonkin,Maksim Mamonkin +17 more
TL;DR: It is found that tonic CAR-derived 4-1BB signaling can produce toxicity in T cells via continuous TRAF2-dependent activation of the nuclear factor κB (NF-κB) pathway and augmented FAS-dependent cell death.